Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias T Stephan

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Nature Biomedical Engineering|December 11, 2019
Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumoursMichael E Coon, Sirkka B Stephan, Vikas Gupta, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 18, 2013
In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomesYiran Zheng, Matthias T Stephan, S Annie Gai, et al.
Cancer Research|May 16, 2018
Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid MalignanciesFan Zhang, Sirkka B Stephan, Chibawanye I Ene, et al.
Nature Biotechnology|December 16, 2014
Biopolymer implants enhance the efficacy of adoptive T-cell therapySirkka B Stephan, Alexandria M Taber, Ilona Jileaeva, et al.
Nature Medicine|November 21, 2007
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejectionMatthias T Stephan, Vladimir Ponomarev, Renier J Brentjens, et al.
Nature Nanotechnology|April 19, 2017
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriersTyrel T Smith, Sirkka B Stephan, Howell F Moffett, et al.
The Journal of Clinical Investigation|April 25, 2017
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumorsTyrel T Smith, Howell F Moffett, Sirkka B Stephan, et al.
Nature Materials|February 22, 2011
Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responsesJames J Moon, Heikyung Suh, Anna Bershteyn, et al.
Nature Reviews. Drug Discovery|September 30, 2025
In vivo chimeric antigen receptor (CAR)-T cell therapyAdrian Bot, Andrew Scharenberg, Kevin Friedman, et al.
Cancer Cell|April 16, 2015
Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2Eric F Zhu, Shuning A Gai, Cary F Opel, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Nature Biomedical Engineering|December 11, 2019
Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumoursMichael E Coon, Sirkka B Stephan, Vikas Gupta, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 18, 2013
In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomesYiran Zheng, Matthias T Stephan, S Annie Gai, et al.
Cancer Research|May 16, 2018
Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid MalignanciesFan Zhang, Sirkka B Stephan, Chibawanye I Ene, et al.
Nature Biotechnology|December 16, 2014
Biopolymer implants enhance the efficacy of adoptive T-cell therapySirkka B Stephan, Alexandria M Taber, Ilona Jileaeva, et al.
Nature Medicine|November 21, 2007
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejectionMatthias T Stephan, Vladimir Ponomarev, Renier J Brentjens, et al.
Nature Nanotechnology|April 19, 2017
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriersTyrel T Smith, Sirkka B Stephan, Howell F Moffett, et al.
The Journal of Clinical Investigation|April 25, 2017
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumorsTyrel T Smith, Howell F Moffett, Sirkka B Stephan, et al.
Nature Materials|February 22, 2011
Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responsesJames J Moon, Heikyung Suh, Anna Bershteyn, et al.
Nature Reviews. Drug Discovery|September 30, 2025
In vivo chimeric antigen receptor (CAR)-T cell therapyAdrian Bot, Andrew Scharenberg, Kevin Friedman, et al.
Cancer Cell|April 16, 2015
Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2Eric F Zhu, Shuning A Gai, Cary F Opel, et al.
Pageof 3